Compare VanEck Australian Floating Rate ETF (FLOT) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs Zoetis Inc — how do they compare? VanEck Australian Floating Rate ETF trades at $50.94, while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while VanEck Australian Floating Rate ETF pays none, and VanEck Australian Floating Rate ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| FLOT | ZTS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $51.09 | $156.76 |
52-Week Low | $50.72 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.93, up 0.02% on the day, with a bearish technical signal from moving averages and oscillators neutral. Recent dividends include $0.18 paid on June 4, 2026, and $0.17 scheduled for July 7, 2026. The stock's support and resistance levels are consolidated around $51, indicating limited near-term price movement potential.
Outlook remains cautious due to bearish technical indicators and sensitivity to Federal Reserve rate decisions. Opportunities exist if rate hikes materialize, boosting yield appeal, but risks include inflation persistence and geopolitical tensions affecting Treasury yields. Investors should weigh income stability against interest rate volatility.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
